The interleukin-6 (IL-6) receptor monoclonal antibody tocilizumab is included in the international guidelines for the treatment of COVID-19, as the RECOVERY [1] and REMAP-CAP [2] trials observed that the use of tocilizumab in combination with dexamethasone moderately improves mortality in COVID-19 patients with a severe disease course, worsening condition, increased oxygen demand, and significant inflammatory response [3]. This evidence concerns the gene IL6 and COVID-19.